ALZN (Alzamend Neuro) Cash per Share : $0.58 (As of Jan. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Alzamend Neuro Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Alzamend Neuro's Cash per Share for the quarter that ended in Jan. 2025 was $0.58.

Alzamend Neuro Cash per Share Historical Data

The historical data trend for Alzamend Neuro's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alzamend Neuro Cash per Share Chart

Alzamend Neuro Annual Data

Trend

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Cash per Share

Get a 7-Day Free Trial

0.15

3.41

22.08

7.96

0.55

Alzamend Neuro Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Cash per Share	Get a 7-Day Free Trial															0.43	0.55	1.39	0.78	0.58

Alzamend Neuro Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Alzamend Neuro's Cash per Share for the fiscal year that ended in Apr. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0.376	/	0.69
	=	0.55

Alzamend Neuro's Cash per Share for the quarter that ended in Jan. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	3.358	/	5.80
	=	0.58

Alzamend Neuro (NAS:ALZN) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Alzamend Neuro Cash per Share Related Terms

Thank you for viewing the detailed overview of Alzamend Neuro's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Alzamend Neuro Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alzamend Neuro Inc (NAS:ALZN) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326

Website

https://www.alzamend.com

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Executives

William B. Horne	director	C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626
Ault Milton C Iii	10 percent owner	11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141
David J Katzoff	officer: Chief Operating Officer	201 SHIPYARD WAY, NEWPORT BEACH CA 92663
Stephan Jackman	director, officer: Chief Executive Officer	C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Lynne Fahey Mcgrath	director	28145 CEDAR POINT RD., EASTON MD 21601
Mark Gustafson	director	10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9
Henry Carl Nisser	director, officer: Exec VP and General Counsel	100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017
Kenneth S Cragun	officer: SVP of Finance	3775 CHIPPEWA CIRCLE, CORONA CA 92881
Jeffrey Oram	director	15 ORCHARD STREET, MENDHAM NJ 07945
Escalona Lien	officer: Chief Financial Officer	C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612
Andrew H. Woo	director	2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404